Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Evaluation of 1st WHO anti-malaria reference reagent for competition ELISA harmonisation and development of ADAMSEL analytical platform.

Khatri B., Riese P., Shkarlet H., Mortier D., McShane H., Bowyer PW., Remarque E.

This study focuses on harmonising the competition ELISA (cELISA) assay for Plasmodium falciparum (P. falciparum), using the 1st WHO reference reagent for anti-malaria (P. falciparum) human reference serum (10/198). Antibody-mediated immune responses against the Apical Membrane Antigen 1 (AMA1) play a significant role in protection against malaria. However, the sequence diversity of AMA1 and cross-reactivity among variants pose challenges in assessing antibody responses. To address this, the cELISA assay was selected to examine cross-reactive antibody responses against different variants. The harmonisation process for cELISA was performed in three laboratories. The 10/198 served as an internal standard for the calculation of IgG concentrations in the cELISA using ADAMSEL software. Additionally, a novel semi-automated analytical tool was developed in the R-statistics environment. This tool is freely available for download and streamlines generating results while minimising human error. This study demonstrated the effectiveness of the 1st WHO reference reagent as a standard for cELISA. Additionally, the ADAMSEL software and R-platform tool provide a user-friendly and accessible tool for the analysis of cELISA data. Its automation capabilities improve efficiency and ensure global accessibility at no cost, benefitting laboratories with limited resources.

More information Original publication

DOI

10.1016/j.biologicals.2025.101850

Type

Journal article

Publication Date

2025-11-01T00:00:00+00:00

Volume

92

Addresses

M, e, d, i, c, i, n, e, s, , a, n, d, , H, e, a, l, t, h, c, a, r, e, , p, r, o, d, u, c, t, s, , R, e, g, u, l, a, t, o, r, y, , A, g, e, n, c, y, ,, , B, l, a, n, c, h, e, , L, a, n, e, ,, , S, o, u, t, h, , M, i, m, m, s, ,, , P, o, t, t, e, r, s, , B, a, r, ,, , H, e, r, t, f, o, r, d, s, h, i, r, e, ,, , E, N, 6, , 3, Q, G, ,, , U, K, ., , E, l, e, c, t, r, o, n, i, c, , a, d, d, r, e, s, s, :, , b, h, a, g, w, a, t, i, ., k, h, a, t, r, i, @, m, h, r, a, ., g, o, v, ., u, k, .

Keywords

Humans, Plasmodium falciparum, Malaria, Falciparum, Immunoglobulin G, Membrane Proteins, Protozoan Proteins, Antibodies, Protozoan, Antigens, Protozoan, Enzyme-Linked Immunosorbent Assay, Reference Standards, Software, World Health Organization